On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...
4don MSN
We recently compiled a list of the 8 Dividend Giants with Lowest Short Interest in 2024. In this article, we are going to ...
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...
As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...
We recently compiled a list of the 10 Best Beaten Down Dividend Stocks to Invest in Now. In this article, we are going to ...
Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could offer insights into the health of the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback